Sign In
Buy FWBI
$2.96
+0 (+0%)
At Close: Aug 15, 2024
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
07:00am, Wednesday, 17'th Jan 2024
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializi
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
06:00am, Thursday, 04'th Jan 2024
Multiple clinical and development milestones anticipated in 2024, including initiation of Phase 3 clinical trial investigating latiglutenase in celiac disease in the event the company closes its poten
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing
Why Is First Wave Biopharma (FWBI) Stock Up 148% Today?
10:29am, Wednesday, 27'th Dec 2023
First Wave Biopharma (NASDAQ: FWBI ) stock is soaring over 140% today. This comes after First Wave announced that it has entered into a non-binding agreement to sell its potential treatment for infl
First Wave BioPharma's stock more than doubles after deal to sell its IBD treatment
06:37am, Wednesday, 27'th Dec 2023
Shares of First Wave BioPharma Inc. FWBI, -5.99% rocketed 123% in premarket trading, which puts them on track for a record one-day gain, after the biopharmaceutical company announced an agreement to s
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
06:00am, Wednesday, 27'th Dec 2023
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase F
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma's late-stage gastrointestinal (GI) disease clinical pipeline
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference
07:00am, Tuesday, 03'rd Oct 2023
BOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializi
First Wave BioPharma To Present at the BIO Investor Forum
08:45am, Friday, 15'th Sep 2023
BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the
First Wave BioPharma stock soars in active trading after Sanofi license deal
07:07am, Thursday, 14'th Sep 2023
Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
11:54am, Friday, 14'th Jul 2023
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.
First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study
11:27am, Wednesday, 14'th Jun 2023
First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
07:00am, Monday, 15'th May 2023
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing
First Wave BioPharma to Present at the BIO CEO & Investor Conference
07:00am, Monday, 30'th Jan 2023
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing
Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?
11:36am, Wednesday, 25'th Jan 2023
Many Nasdaq stocks were in the red this morning, but not First Wave BioPharma (NASDAQ: FWBI ) stock. Indeed, First Wave shares were up substantially after the company announced an addition to its int
